Synexus Czech s.r.o.

Prague 20 trials 5 recruiting

20 Registered trials

5 Currently recruiting

Organisation

Synexus Czech s.r.o.

Location

Prague, Czechia

Identifier

ORG-100040880

Address

Karlovo Namesti 2097/10, Nove Mesto, 120 00, Czechia

Departments

202: nap
Chronic pain
Clinical Trials Center
CZ10008
Gastroenterology clinic
Internal medicine
Klinika Praha
N/A
NA

Clinical trials at this site (20)

Search interface

A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Ended

2025-523974-18-00 Obesity 5 2026-04-30
A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended

2024-518343-38-00 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amy 5 2025-02-12
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr… Ended

2023-508248-23-00 Non-alcoholic steatohepatitis (NASH) 5 2021-11-26
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended

2022-502841-91-00 Crohn’s Disease 5 2020-08-12
A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended

2024-518318-25-00 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amy 5 2020-06-24
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504718-31-00 Moderately to Severely Active Ulcerative Colitis 10 2019-10-19
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504736-18-00 Moderately to Severely Active Crohn's Disease 10 2018-07-26
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended

2022-502778-18-00 ulcerative colitis 5 2023-11-17
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended

2022-502234-70-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-07-14
Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosis Ended

2024-513591-18-00 Postmenopausal osteoporosis 5 2023-04-26
Long-term Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis Ended

2023-503600-83-00 Moderate to Severe Plaque Psoriasis 5 2020-05-27
A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended

2023-508364-29-00 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amy 5 2019-11-22
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and… Ended

2024-512417-41-00 Osteoporosis 5